1. Introduction {#sec1}
===============

Oxidative stress induced by the presence of free radicals which can damage cell membranes, membrane lipids and nucleic acids. This process has been noticed in the pathogen of aging and other diseases such as cancer, atherosclerosis, and Alzheimer\'s disease ([@bib11]; [@bib27]). As a result, the elimination of free radicals and related species has attracted much attention in recent years. Heterocyclic compounds show best interests in this subject, such as 1,3-thiazole, which is one of the important five-membered rings containingnitrogen and sulfur as heteroatoms ([@bib25]). It\'s a known scaffold as a potential pharmacophore in many biological activities ([@bib1]; [@bib14]; [@bib22]; [@bib32]; [@bib35]; [@bib36]). In addition, pyrazole, which is a five-membered heterocyclic ring containing two adjacent nitrogen, can be found in many industrial fields ([@bib7]; [@bib17]; [@bib19]; [@bib37]). The pyridine,a six-membered heterocyclic ring contains a only one nitrogen used for many applications ([@bib6]; [@bib29]). Based on a search made by Web of science database; from 1993 to 2018, the number of documents per year for these three heterocyclic moieties has known a remarkable increase as a represented in Figures [1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, and [3](#fig3){ref-type="fig"}.Figure 1Citation report of \"Thiazole and antioxidant\" in web of science from 1993 to 2018.Figure 1Figure 2Citation report of \"Pyrazole and antioxidant\" in web science from 1993 to 2018.Figure 2Figure 3Citation report of \"Pyridine and antioxidant\" in web of science from 1993 to 2018.Figure 3

In the literature, there are many studies about antioxidant activity of heterocyclic compounds, and the closest ones are the N-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)pyridin-4-amine derivatives ([@bib2], [@bib3]) which is represented in the [Figure 4](#fig4){ref-type="fig"}, where the compounds show good results of 27.51, 15.89, 28.11 and 57.12 mg/mL for IC~50~of 1, 3, 8 and 10 respectively.Figure 4General reaction of the N-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)pyridin-4-amine derivatives ([@bib2], [@bib3]).Figure 4

These results drive us firstly to prepare new heterocyclic compounds containing these cores, and then evaluate their antioxidant activity using DPPH scavenging method. Secondly, to investigate their molecular reactivity relationship based on DFT and molecular docking with the Urate oxidase.

The three-dimensional structure of the studied protein is Urate oxidase from aspergillus flavus complexed with its inhibitor oxonic acid (PDB: 1R4U) ([@bib31]) shown in [Figure 5](#fig5){ref-type="fig"}, is an essential enzyme responsible for the first step in the degradation of uric acid to allantoin by formation of the intermediate (5-hydroxyisourate) and H~2~O~2~ as by-product ([Figure 6](#fig6){ref-type="fig"}). This enzyme demonstrated its activity to oxidize the uric acid, and it described in the literature as one of the proteins docked to study theoretically the antioxidant activity ([@bib31]; [@bib33]).Figure 5The three-dimensional structure of the urate oxidase from aspergillus flavus complexed with its inhibitor oxonic acid (PDB:1R4U).Figure 5Figure 6The schematic degradation of uric acid to (5-hydroxyisourate) then allantoin ([@bib31]).Figure 6

2. Materials and methods {#sec2}
========================

2.1. General information {#sec2.1}
------------------------

For the chemical analysis of the prepared ligands, several physicochemical methods were used such as NMR by AVANCE 400 and 500 MHz of BRUKER to verify the structure of the product, using CDCl~3~, CD~2~Cl~2~ and DMSO-d~6~ as a solvent for ^1^H NMR and ^13^C NMR. The FTIR analyses were done by FTIR 8400S spectrophotometer recorded in KBr pellets.

2.2. Compounds synthesis {#sec2.2}
------------------------

•**N,N-bis((1H-pyrazol-1-yl)methyl)thiazol-2-amine ([1]{.ul}):**For this preparation, 1g of 2-aminothiazole (9.98 mmol) and 1.96g of (1H-pyrazol-1-yl)methanol (19.9mmol) were mixed together in acetonitrile under reflux for 4 h, and the solvent was evaporated then recrystallized in diethyl ether then filtrated to have the final product (2.58 g, 90%): **mp** 84--86 °C, **FTIR (KBr, cm**^**−1**^**):** 3025 (C--H); 1560 (C=C); 1540 (C--C); 1386 (C--N); 1159 (C=N); 1050 (N--N); 754 (=C--H); 692 (C--S), ^**1**^**H NMR(CD**~**2**~**Cl**~**2**~**, 500MHz) δ ppm:** 7.79 (d, 2H, CH (5, Pyrazole), J~H-H~ = 5 Hz); 7.55 (d, 1H, CH--N, J~H-H~ = 5 Hz); 7.17 (d, 2H, CH (3, Pyrazole), J~H-H~ = 5 Hz); 6.62 (d, 1H, CH--S); 6.28 (t, 2H, CH (4, Pyrazole), J~H-H~ = 5 Hz); 5.56 (s, 4H, CH~2~), ^**13**^**C NMR(CD**~**2**~**Cl**~**2**~**, 500MHz) δ ppm:** 167.75 (C--N); 139.80 (CH (3, Pyrazole)); 138.79 (CH--N); 129.53 (CH (5, Pyrazole)); 109.76 (CH--S); 105.42 (CH (4, Pyrazole)); 59.81 (CH~2~).•**N, N-bis((1H-pyrazol-1-yl)methyl)pyridin-4-amine[(2)]{.ul}:** For this preparation, 0.43g of 4-aminopyridine (4.55 mmol) and 0.89g of (1H-pyrazol-1-yl)methanol (9.07 mmol) were mixed together in acetonitrile under reflux for 4 h, and the solvent was evaporated then recrystallized in diethyl ether then filtrated to have the final product (0.67 g, 57%): **mp**68-70 °C; **FTIR (KBr, cm**^**−1**^**):** 2372 (C--H); 1600 (C=C); 1564 (C--C); 1398 (C--N); 1306 (C=N); 1112 (N--N); 805 (=C--H), ^**1**^**H NMR(DMSO, 500MHz) δ ppm:** 8.10 (d, 2H, CH=N (pyridine), J~H-H~ = 5 Hz); 7.79 (d, 2H, CH (5, pyrazole), J~H-H~ = 5 Hz); 7.52 (d, 2H, CH (3, pyrazole), J~H-H~ = 5 Hz); 6.78 (d, 2H, CH=C--N, J~H-H~ = 5 Hz); 6.26 (t, 2H, CH (4, Pyrazole), J~H-H~ = 5 Hz); 5.40 (s, 2H, CH~2~), ^**13**^**C NMR(DMSO, 500MHz) δ ppm:** 152.89 (C--N); 150.02 (CH=N (pyridine)); 139.43 (CH (3, pyrazole)); 129.85 (CH (5, pyrazole)); 108.62 (CH=C--N); 106.10 (CH (4, Pyrazole)); 73.73 (CH~2~).•**N, N-bis((3,5-dimethyl-1H-pyrazol-1-yl)methyl)pyridin-4-amine[(3)]{.ul}:** For this preparation, 0.5g of 4-aminopyridine (5.31 mmol) and 1.34g of (3,5-dimethyl-1H-pyrazol-1-yl)methanol (11mmol) were mixed together in acetonitrile under reflux for 4 h, and the solvent was evaporated then recrystallized in diethyl ether then filtrated to have the final product (0.48 g, 29%): **mp** 100--102 °C, **FTIR (KBr, cm-1):** 2359 (C--H); 1648 (C=C); 1559 (C--C); 1454 (C--N); 1310 (C=N); 1071 (N--N); 807 (=C--H), ^**1**^**H NMR(CDCl**~**3**~**, 500MHz) δ ppm:** 7.66 (d, 2H, C**H**=N (pyridine), J~H-H~ = 5 Hz); 7.24 (d, 2H, CH=C--N, J~H-H~ = 5 Hz); 6.24 (s, 2H, CH (4, Pyrazole)); 5.66 (s, 4H, CH~2~); 2.34 (s, 6H, CH~3~ (5, pyrazole)); 2.09 (s, 6H, CH~3~ (3, pyrazole)), ^**13**^**C NMR(CDCl**~**3**~**, 500MHz) δ ppm:** 167.73 (C--N (pyridine)); 156.11 (C=N); 140.41 (C--H (3, pyridine)); 138.13 (C--H (5, pyridine)); 113.78 (CH--CH=N); 105.50 (CH (Pyrazole)); 57.61 (CH~2~); 14.02 (CH~3~ (3, pyrazole)); 10.96 (CH~3~ (5, pyrazole)).•**N,N-bis((3,5-dimethyl-1H-pyrazol-1-yl)methyl)thiazol-2-amine[(4)]{.ul}** ([@bib16]): For this preparation, 1.5g of 2-aminothiazole (0.0149 mol) and 3.78g of (3,5-dimethyl-1H-pyrazol-1-yl)methanol (0.0299 mol) were mixed together in acetonitrile under reflux for 4 h, and the solvent was evaporated then recrystallized in diethyl ether then filtrated to have the final product (3.58 g, 76%);**FTIR (KBr, cm**^**−1**^**):** 3040 (C--H); 1558 (C=C); 1542 (C--C); 1320 (C--N); 1170 (C=N); 1030 (N--N); 742 (=C--H); 680 (C--S), ^**1**^**H NMR(DMSO, 400MHz) δ ppm:** 7.57 (d, 1H, CH--N (Thiazole), J~H-H~ = 5 Hz); 6.90 (d, 1H, CH--S (Thiazole), J~H-H~ = 5 Hz); 6.12 (s, 2H, CH (4, Pyrazole)); 5.59 (s, 4H, CH~2~); 2.5 (s, 6H, CH~3~ (5, pyrazole)); 2.16 (s, 6H, CH~3~ (3, pyrazole)), ^**13**^**C NMR(DMSO, 400MHz) δ ppm:** 153.64 (C--N); 146.94 (C--CH~3~ (3, pyridine)); 140.15 (C--CH~3~ (5, pyridine)); 133.32 (CH--N (Thiazole)); 113.53 (CH--S (Thiazole)); 105.79 (CH (4, Pyrazole)); 61.32 (CH~2~); 13.83 (CH~3~ (3, pyrazole)); 10.29 (CH~3~ (5, pyrazole)).•**4-(bis((1H-pyrazol-1-yl)methyl)amino)phenol[(5)]{.ul}:** For this preparation, 0.9g of 4-aminophenol (8.24 mmol) and 2g of (1H-pyrazol-1-yl)methanol (20 mmol) were mixed together in acetonitrile under reflux for 4 h, and the solvent was evaporated then recrystallized in diethyl ether then filtrated to have the final product (1.79 g, 81%): **mp** 158--160 °C, **FTIR (KBr, cm**^**−1**^**):** 3113 (O--H); 2300 (C--H); 1659 (C=C); 1509 (C--C); 1393 (C--N); 1183 (C=N); 1039 (N--N); 750 (=C--H), ^**1**^**H NMR(DMSO, 500MHz) δ ppm:** 8.75 (s, 1H, OH); 7.86 (d, 2H, CH (5, pyrazole), J~H-H~ = 5 Hz); 7.58 (d, 2H, CH (3, pyrazole), J~H-H~ = 5 Hz); 6.97 (m, 4H, CH (phenyl), J~H-H~ = 5 Hz); 6.31 (t, 2H, CH (4, pyrazole), J~H-H~ = 5 Hz); 5.99 (s, 4H, CH~2~), ^**13**^**C NMR(DMSO, 500MHz) δ ppm:** 167.79 (C--N); 139.68 (CH (3, phenyl)); 138.99 (C--OH); 130.48 (CH (5, phenyl)); 129.32 (CH (5, pyrazole)); 110.42 (CH (3, pyrazole)); 105.91 (CH (4, pyrazole)); 59.09 (CH~2~).•**5-bromo-N-((3,5-dimethyl-1H-pyrazol-1-yl) methyl) pyridin-2-amine[(6)]{.ul}:** For this preparation, 1g of 3-amino-4-bromopyridine (5.8 mmol) and 1.46g of (3,5-dimethyl-1H-pyrazol-1-yl)methanol (11.6 mmol) were mixed together in acetonitrileunder reflux for 4 h, and the solvent was evaporated then recrystallized in diethyl ether then filtrated to have the final product (1.72 g, 76%);**FTIR(KBr, cm**^**−1**^**):** 3040 (C--H); 1558 (C=C); 1542 (C--C); 1320 (C--N); 1170 (C=N); 1030 (N--N); 742 (=C--H); 680 (C--S), ^**1**^**H NMR(DMSO, 400MHz) δ ppm:** 7.57 (d, 1H, CH--N (Pyridine), J~H-H~ = 5 Hz); 6.90 (d, 2H, CH=CH (Pyridine), J~H-H~ = 5 Hz); 6.12 (s, 1H, CH (4, Pyrazole)); 5.76 (t, NH, J~H-H~ = 5 Hz); 5.59 (d, 4H, CH~2~, J~H-H~ = 5 Hz); 2.5 (s, 3H, CH~3~ (5, pyrazole)); 2.16 (s, 3H, CH~3~ (3, pyrazole)), ^**13**^**C NMR(DMSO, 400MHz) δ ppm:** 153.64 (C--N); 146.94 (C--CH~3~ (3, pyridine)); 140.15 (C--CH~3~ (5, pyridine)); 133.32 (CH--N (Pyridine)); 113.53 (CH=CH (Pyridine)); 105.79 (CH (4, Pyrazole)); 61.32 (CH~2~); 13.83 (CH~3~ (3, pyrazole)); 10.29 (CH~3~ (5, pyrazole)).

2.3. DFT calculations {#sec2.3}
---------------------

The DFT study was executed on Dell OptiPlex 790 MT - Core i5-2400 @ 3,10 GHZ with 4 GB RAM PC-based - Windows 7 Pro 64 Bits as operating system. Full geometry optimization of the studied molecules have been performed using **[Gaussian 09W software]{.ul}** ([@bib12]) by the Density Functional Theory (DFT) method with the 3 functional parameters of Becke associated with the functional correlation gradient corrected of Lee Yang Parr (B3LYP) exchange correlation ([@bib4]; [@bib5]; [@bib21]) in combination with 6-31G (d, p) orbital basis sets for all atoms. No symmetry constrains was applied during the geometry optimization. Molecular Electrostatic Potential (MEP) maps of the optimized structures were calculated and generated by GaussView 06 software.

2.4. Molecular docking {#sec2.4}
----------------------

The crystal structure of the Urate oxidase (PDB: 1R4U) ([@bib31]) was downloaded from Protein Database Bank ([www.rcsb.org](http://www.rcsb.org){#intref0010}) then used as a biological target in the docking study. The sequence of the protein was edited by removing water molecules and cofactors using default parameters included in **[MOE software]{.ul}**. The active site was searched using the site finder tool. The docking was launched after protonating the protein at pH = 7 and adding partial charges. The complex was optimized under MMFF94X forcefield. Protein was kept in a rigid conformation while ligands in flexible conformation.

2.5. Antioxidant activity {#sec2.5}
-------------------------

DPPH ((1,1-diphenyl-2-picrylhydrazyl) assay was used in this work to evaluate the antioxidant potential of all the prepared compounds ([@bib8]). Briefly, 2 mg of DPPH was dissolved in 100 mL of Methanol to obtain the solution (**M)**. On the other side, the concentration ranging from 2 to 500 μg/mL of both ligands and ascorbic acid (positive control) was prepared. For our tests, 0.5mL of (**M**) was mixed with 0.5 mL of each ligand, then incubated in the dark for 30 min, the absorbance of each mixture was measured with the aid of a UV spectrophotometer at 517 nm.

However, the activity is defined by the percentage of the scavenging activity calculated using the following equation:$$\% scavenging\ activity = {(A_{control} - A_{Sample}/A_{control})} \times 100$$Where A~control~ is the absorbance of the blank (DPPH alone) and A~Sample~: the absorbance of the tested solution after t = 30 min.

3. Results and discussion {#sec3}
=========================

3.1. Chemistry {#sec3.1}
--------------

A library of tridentate pyrazolic compounds 1--6 was prepared according to (Figures [7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}) by condensation of the (3,5-dimethyl-1H-pyrazol-1-yl) methanol (R~1~ = CH~3~) and the Pyrazol-1-yl-methanol (R~1~ = H) ([@bib10]) with appropriate primary amines under reflux in acetonitrile for 4 h by following the literature procedure ([@bib2], [@bib3]; [@bib15]; [@bib26]; [@bib30]).Figure 7The general procedure for the preparation of the ligands **[1]{.ul}**-**[6]{.ul}**.Figure 7Figure 8The chemical structures of the prepared ligands **[1]{.ul}**-**[6]{.ul}**.Figure 8

The chemical structure of the studied ligands was verified by the absence of OH in the ligand spectrum, as an example: NMR spectrum superposition of the ligand 1 with Pyrazol-1-yl-methanolrepresented in [Figure 9](#fig9){ref-type="fig"}.Figure 9OH region representation in 1H NMR spectrum of the ligand (**[1]{.ul}**) (**[Red]{.ul}**) superposed with the spectrum of Pyrazol-1-yl-methanol (**[Blue]{.ul}**).Figure 9

3.2. Antioxidant activity (DPPH assay) {#sec3.2}
--------------------------------------

[Table 1](#tbl1){ref-type="table"} which represent the IC~50~ values of each studied ligand either in μg/ml and μM, show us the IC~50~ of the different ligands where we see that the ligand [(]{.ul}**[4]{.ul}**[)]{.ul} has the best IC~50~ value with 4.67 μg/mL compared to the IC~50~ of the Ascorbic acid which is 2 μg/mL.Table 1The IC~50~ antioxidant activity results of synthesized compounds (**[1]{.ul}**-**[6]{.ul}**) and the Ascorbic acid reference.Table 1Compound[**1****2****3****4****5****6**]{.ul}Ascorbic acidIC~50~μg/mL20.5645.3233.78**4.67**15.4626.052μM78.98178.21108.82**14.76**57.4166.9111.36

The ligand **[4]{.ul}** has no Proton to give to DPPH radical, but it is rich in electron, and we proposed due it structure that it gives electron to stabilize the DPPH radical; by the delocalization of the electron over the molecule so it doesn\'t dimerize, as the most other free radicals ([@bib24]). For the stabilization of free radicals, in our case the DPPH are either by Proton or electron donation ([@bib13]; [@bib24]), or called as redox based reaction (ET: Electron Transfer or HAT: Hydrogen atom transfer that react either with reactive oxygen species (ROS) or reactive nitrogen species (RNS) ([@bib23]). This pushes us to do theoretical investigations to have more insights about the molecular reactivity of our studied ligands (1--6).

3.3. Theoretical investigations {#sec3.3}
-------------------------------

### 3.3.1. DFT calculations {#sec3.3.1}

The determination of the electronic parameters of a molecule is an efficient tool to predict and interpret its reactivity in several types of reactions and remains a powerful technique to explain the biological activity results ([@bib9]; [@bib18]). The frontier molecular orbital HOMO (The highest occupied molecular orbital) and LUMO (The lowest unoccupied molecular orbital) present important descriptors that can use it to determine the electron donating and receiving ability of a molecule. Additionally, the energy gap (ΔE = E~LUMO~ − E~HOMO~) is a very established indicator of the chemical reactivity and stability, it is a measure of the intramolecular charge transfer. Generally, molecules with a large energy gap are associated with less chemical reactivity and high kinetic stability, and vice versa for molecules with a small energy gap ([@bib20]). In our case, these parameters were calculated for the most active antioxidant compound (compound **[4]{.ul}**) and the less active one (compound **[2]{.ul}**) after full-geometry optimization at DFT/B3LYP/6-31G (d,p) level. The shapes of MOs frontiers HOMO and LUMO and their energy values were determined and displayed in the [Figure 10](#fig10){ref-type="fig"}.Figure 10Shapes of HOMO, LUMO of compounds **[2]{.ul}** and **[4]{.ul}** in correlation with the antioxidant activity. Positive and negative phases are shown in red and green colors, respectively.Figure 10

From the DFT results, LUMO energies of **[2]{.ul}** and **[4]{.ul}** were found in order of -0.552 and -0.016eV respectively. HOMO energies were -6.260 eV for compound **[2]{.ul}** and -5.523 eV for compound **[4]{.ul}**, leading to energy gap values of 5.707 and 5.507 eV for **[2]{.ul}** and **[4]{.ul}** respectively, which means that compound **[4]{.ul}** is less stable (therefore more active) than compound **[2]{.ul}** because it opposes less charge transfer and changes in its electron density. In conclusion, these findings agree with our experimental results. The general shape of the molecular orbital and its location also represents an additional factor that can affect the biological activity of a molecule. It can be affected easily by the presence (or not) of electron-donating or withdrawing groups.

From the [Figure 10](#fig10){ref-type="fig"}, the HOMOs are delocalized over the entire molecule for compound **[2]{.ul}**, and mainly localized over thiazole ring, sp^3^-nitrogen atom of the bridge bond and on one of pyrazolerings for compound **[4]{.ul}**. The empty LUMO orbital is located on the pyridine ring, sp^3^-nitrogen atom of the bridge bond and one of the pyrazole moieties, while it has its major contribution from thiazole ring, and sp^3^-nitrogen atom of the bridge bond for compound **[4]{.ul}**.

On the other hand, several other chemical descriptors such as chemical hardness (η) and softness (σ) can also present a way to measure the reactivity of molecules ([@bib34]). Their values are generally calculated from the HOMO and LUMO energies. The results are collected in the [Table 2](#tbl2){ref-type="table"} below. Compound **[2]{.ul}** showed a chemical hardness value of 2.853 eV higher than that of compound **[4]{.ul}** (2.753 eV) which means that this compound resists more towards the deformation of the electron density distribution, hence more stable and less reactive compared to **[4]{.ul}**. In general, high chemical hardness values characterize stable, hence low reactive compounds, whilst high values of softness, denote low stable compounds with high reactivity. All these observations were found to support the experimental antioxidant findings.Table 2The calculated molecular descriptors of compounds **[2]{.ul}** and **[4.]{.ul}**Table 2Chemical reactivity indices (eV)[**2****4**]{.ul}*E*~HOMO~- 6.260-5.523*E*~LUMO~- 0.552- 0.016Δ*E* = *E*~LUMO~ - *E*~HOMO~5.7075.507Chemical hardness (η = (*E*~LUMO~ - *E*~HOMO~)/2)2.8532.753Softness (σ = 1/η)0.3500.363

Finally, in order to determine the distribution of the electronic charge over all the structure, a molecular electrostatic potential (MEP) map was generated for each studied compound (i.e. **[2]{.ul}** and **[4]{.ul}**). In fact, MEP plot is very utilized as a powerful tool to identify the reactive sites for nucleophilic and electrophilic attacks on a molecule, to study the hydrogen bonding interactions and as well as the biological recognition processes ([@bib28]). Analyzing the created MEP maps for both compounds **[2]{.ul}** and **[4]{.ul}** ([Figure 11](#fig11){ref-type="fig"}), the highly negative electrostatic potential regions (red color) are mainly concentered over the nitrogen atoms of the pyridine and the pyrazole rings for compound **[2]{.ul}** with values of- 1.387 and -1.333eV (at an isovalue of 0.0004 electrons/Å^3^) respectively, in time the highly positive regions (blue color) are localized on the nitrogen atom of the second pyrazole ring. For compound **[4]{.ul}**, the negative values are mainly located over the nitrogen atom of pyrazole ring with a value of -1.363 eV (low values were recorded over the nitrogen and sulfur atoms of the thiazole ring (yellow color)), while the plot showed low positive values focused mainly over the methyl groups (green color). These findings can be used to predict the possible sites for electrophilic attacks, a thing that can explain the docking results mentioned below with regard to the binding of each molecule to the residues of the active site of the studied protein.Figure 11Molecular electrostatic potential (MEP) maps of compound **[2]{.ul}** (left) and compound **[4]{.ul}** (right). Negative regions are represented by red, orange and yellow colors, whilepositive regions are illustrated by green and blue colors. The electrostatic potential at the surface increases in the order red \< orange \< yellow \< green \< blue.Figure 11

### 3.3.2. Molecular docking {#sec3.3.2}

In order to understand and identify the molecular interactions between the ligand and the active site residues of the studied target protein; molecular docking was conducted employing Molecular Operating Environment (MOE) software. Crystal structure of the Urate oxidase (PDB entry 1R4U) was used in this study. The calculations were carried out keeping the default parameters of the MOE program.

As a first step, the docking reliability was checked by re-docking the native ligand (oxonic acid) into the binding site of Urate oxidase protein. The docking calculation showed that the predicted pose of re-docked ligand was found to be identical to that of the native ligand with rmsd = 0.970 Å ([Figure 12](#fig12){ref-type="fig"}) with a binding score of -4.45 kcal/mol. Predicted pose showed H-bonding interactions with amino acid residues Gln228, Val227 and Arg176 which is in total agreement with that shown in the experimental part.Figure 123D (left) and 2D (middle) interactions of native ligand (oxonic acid) after re-docking protocol. Most-right figure represents the experimental interactions of the native ligand.Figure 12

In our present work, and based on the in vitro antioxidant assay findings, the two compounds **[2]{.ul}** and **[4]{.ul}**, which present the less and the most active compounds respectively, were docked into the active site of Urate oxidase protein. The molecular docking data are calculated and reported in [Table 3](#tbl3){ref-type="table"}.Table 3The docking calculations of compounds **[2]{.ul}** and **[4]{.ul}**.Table 3CompoundΔG~binding~ (kcal/mol)Interaction(C-AA)Bond length (Å)**[2]{.ul}**-4.96N(pyridine) -- H(Val227)2.70Pyridine ring -- H(Arg176)3.87**[4]{.ul}**-5.45N(pyrazole) -- H(Arg176)2.39Pyrazole ring -- H(Leu170)2.98H(CH~3~) -- Phenyl (Phe159)3.04Pyrazole ring -- H(His256)3.43[^1]

According to the docking results, compound **[4]{.ul}** showed a binding affinity to Urate oxidase protein higher than shown by compound **[2]{.ul},** the values are equal to-5.45 and -4.96 kcal/mol for **[4]{.ul}** and **[2]{.ul}** respectively. As shown in [Table 3](#tbl3){ref-type="table"} and depicted in [Figure 13](#fig13){ref-type="fig"}, both ligands interact with amino acid residues of Urate oxidase. Compound **[2]{.ul}** was found to establish one hydrogen bonding interaction of 2.70 Å with amino acid residue Val227 and via the nitrogen atom of the pyridine ring and one π interaction between the pyridine ring and the hydrogen atom of NH~2~ group of the Arg176 residue with a distance of 3.87Å. While, compound **[4]{.ul}** form four interactions divided on one H-bond and three π interactions, the first was formed between the sp^2^nitrogen atom of pyrazole ring and the hydrogen atom of Arg176 residue (2.39Å); two of the π interactions were made between the two pyrazole rings and the Leu170 and His256 residues with Bond length of 2.98 and 3.43 Å respectively; whilst the CH~3~group via its hydrogen atom form the third one with the phenyl ring of Phe159 amino acid (3.04Å). Interestingly, compound **[2]{.ul}** showed interactions with the same amino acids that interact with the native ligand, Val227 and Arg176, which can indicate that this compound can exhibit its action with a similar mechanism like that of the native ligand.Figure 133D binding modes of compound **[2]{.ul}** (left), compound **[4]{.ul}** (right) into the xanthine oxidoreductase binding pocket.Figure 13

Based on the above observations, our docking results revealed that the compound **[4]{.ul}** seems more active than **[2]{.ul}**, which support the experimental antioxidant findings. However, more appropriate experimental tests should and more theoretical investigations by others performing methods should be carried out to confirm the effect of these compounds on Urate oxidase protein.

4. Conclusion {#sec4}
=============

Six ligands were prepared by condensation of 1,3-Thiazole or Pyridine derivatives with 1H-pyrazole or 3,5-dimethylpyrazole to give good yields up to 99%. From the DFT results, compound **[4]{.ul}** is less stable (therefore more active) than compound **[2]{.ul}**. Compound **[2]{.ul}** showed a chemical hardness value of 2.853 eV higher than that of compound **[4]{.ul}** (2.753 eV) which means that this compound resists more towards the deformation of the electron density distribution, hence more stable and less reactive compared to **[4]{.ul}**. In general, high chemical hardness values characterize stable, hence low reactive compounds, whilst high values of softness, denote low stable compounds with high reactivity. All these results support our experimental findings. Based on the above observations, our docking results revealed that compound **[4]{.ul}** seems more active than **[2]{.ul}**, which is in good accordance with the experimental antioxidant findings. However, more experimental tests and theoretical investigations should be carried out by other performing methods to confirm the effect of these compounds on Urate oxidase protein.
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[^1]: C-AA: Interaction between the studied compound and the Amino acid of the Xanthine oxidoreductase sequence.
